On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Treatment of human disease
- Gregor Mendel - 1865
- Archibald Garrod 1908
- Mutation, disease & therapeutic approaches
- DNA structure discovery
- Can DNA be a therapeutic agent?
- Lesch-Nyhan disease
- Metabolic pathway of Lesch-Nyhan disease
- Can we modify cells with foreign DNA? (1)
- Can we modify cells with foreign DNA? (2)
- HPRT(-) cells can't incorporate hypoxanthine
- Transient HPRT expression after transfection
- Viruses as vectors
- Converting normal cells into tumor cells with a virus
- 1972 - human gene therapy paper
- Gene transfer by retrovirus
- Retroviral vector corrects a disease phenotype
- Different vectors for transferring DNA into cells
- Extensive regulation and oversight
- Optimism about human gene therapy (1)
- Optimism about human gene therapy (2)
- A difficult controversial beginning
- Criticism against human gene therapy
- Gene transfer trials by year
- Death from gene therapy trial - 1999 (1)
- Death from gene therapy trial - 1999 (2)
- Severe combined immunodeficiency diseases
- Texas bubble boy
- SCID-X1; Gamma-c deficiency
- Success, but at a cost
- A vector integrated foreign DNA into the lmo2 gene
- Leber's congenital amaurosis
- Why do children with Leber's not see?
- rRPE65 defect in a dog model
- Sub-retinal injection of AAV2.hRPE65v2
- Gene therapy for Leber's amaurosis
- Summary - the reality of gene therapy
Topics Covered
- Background in genetic concepts
- Application by Sir Archibald Garrod to human disease
- Discovery of the structure of DNA and new opportunities to understand and manipulate genes
- Proof of principle of gene transfer into human cells using the Lesch Nyhan disease model
- Rapid expansion of clinical gene therapy trials, high level of optimism and expectation
- Major setback in human OTC gene therapy study
- Patient death
- Scientific and clinical success with another disease model
- Severe combined immunodeficiency (SCID)
- Setback in SCID
- Leukemia in some treated patients
- Additional clinical successes, especially in Leber's congenital blindness
Links
Series:
Categories:
Talk Citation
Friedmann, T. (2010, October 18). The development and evolution of human gene therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/EMRY7540.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Theodore Friedmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.